Our present study found that silencing ORMDL3 increases the inhibitory effect of sorafenib on the viability and proliferation in HCC cells, and increases the sensitivity of HCC cells to sorafenib. The gene discussed is ORMDL3; the disease is hepatocellular carcinoma.